WO2019040612A1 - PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES Download PDF

Info

Publication number
WO2019040612A1
WO2019040612A1 PCT/US2018/047508 US2018047508W WO2019040612A1 WO 2019040612 A1 WO2019040612 A1 WO 2019040612A1 US 2018047508 W US2018047508 W US 2018047508W WO 2019040612 A1 WO2019040612 A1 WO 2019040612A1
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
pharmaceutical composition
composition
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/047508
Other languages
English (en)
French (fr)
Inventor
Steven Andrew LANTZ
Kapil Gupta
Shantanu SULE
Adnan ZUNIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK18762749.2T priority Critical patent/DK3672631T5/da
Priority to SG11202001281WA priority patent/SG11202001281WA/en
Priority to KR1020257011023A priority patent/KR20250053967A/ko
Priority to LTEPPCT/US2018/047508T priority patent/LT3672631T/lt
Priority to RS20230487A priority patent/RS64289B1/sr
Priority to PL18762749.2T priority patent/PL3672631T3/pl
Priority to EP18762749.2A priority patent/EP3672631B9/en
Priority to CN201880066191.8A priority patent/CN111201037B/zh
Priority to CA3073066A priority patent/CA3073066A1/en
Priority to MYPI2020000935A priority patent/MY204563A/en
Priority to EA202090555A priority patent/EA202090555A1/ru
Priority to AU2018321335A priority patent/AU2018321335B2/en
Priority to US16/639,338 priority patent/US11655289B2/en
Priority to SI201830903T priority patent/SI3672631T1/sl
Priority to ES18762749T priority patent/ES2945165T3/es
Priority to MA49947A priority patent/MA49947B1/fr
Priority to JP2020511254A priority patent/JP7263320B2/ja
Priority to KR1020207007477A priority patent/KR102931172B1/ko
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Priority to BR112020003572-6A priority patent/BR112020003572A2/pt
Priority to FIEP18762749.2T priority patent/FI3672631T3/fi
Priority to MX2020001855A priority patent/MX2020001855A/es
Priority to SM20230129T priority patent/SMT202300129T1/it
Priority to IL272773A priority patent/IL272773B2/en
Priority to MDE20200677T priority patent/MD3672631T3/ro
Priority to HRP20230387TT priority patent/HRP20230387T1/hr
Priority to EP23163774.5A priority patent/EP4233901A3/en
Priority to CN202410311745.3A priority patent/CN118370815A/zh
Publication of WO2019040612A1 publication Critical patent/WO2019040612A1/en
Priority to JOJO/P/2020/0041A priority patent/JOP20200041B1/ar
Anticipated expiration legal-status Critical
Priority to CONC2020/0002992A priority patent/CO2020002992A2/es
Priority to JP2022211705A priority patent/JP2023030173A/ja
Priority to US18/300,339 priority patent/US20240043513A1/en
Priority to JP2025124021A priority patent/JP2025175284A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the present application relates generally to pharmaceutical compositions comprising anti-beta amyloid ( ⁇ ) antibodies and uses thereof.
  • ⁇ is a peptide generated from the metabolism of amyloid precursor protein (APP).
  • APP amyloid precursor protein
  • Several ⁇ peptide alloforms exist e.g., ⁇ 40 and ⁇ 42). These monomeric peptides have a variable tendency to aggregate into higher order dimers and oligomers.
  • soluble oligomers may transition into insoluble deposits having a ⁇ pleated sheet structure. These deposits are also referred to as amyloid plaques and are composed of predominantly fibrillar amyloid (Hampel et al., Exp Neurol, 223(2):334-46 (2010); Gregory and Halliday, NeurotoxRes. , 7(l-2):29-41 (2005)).
  • AD Alzheimer's disease
  • AD patients having high serum titers of anti- ⁇ antibodies that recognize amyloid plaques have slower rates of cognitive decline and disability as compared to patients that do not have anti- ⁇ antibodies.
  • patients who develop high titers of anti- ⁇ antibodies show reduced numbers of brain ⁇ plaques and improved cognitive performance assessed after long-term follow up.
  • the anti- ⁇ antibody, BIIB037 is a fully human antibody comprising a glycosylated human IgGl heavy chain and a human kappa light chain. Recombinantly expressed BIIB037 binds with high apparent affinity to high molecular weight aggregates, presumably fibrils, of human ⁇ .
  • BIIB037 shows high affinity binding to ⁇ plaques in human AD brain and in brain tissues derived from human APP -expressing transgenic mice.
  • the affinity and specificity of BIIB037 for high molecular weight aggregates of human ⁇ was confirmed by immunoprecipitation, immunoblotting, and immunohistochemistry.
  • Tg2576 AD transgenic mice BIIB037 treatment results in measurable drug levels in brain as assessed by ELISA. Following administration of ⁇ 037 in Tg2576 mice,
  • Antibody -mediated removal of ⁇ from the brain is hypothesized to decrease ⁇ burden, thereby preventing neuronal dysfunction, slowing the progression of pathology and reducing the rate of cognitive decline in AD.
  • compositions containing anti- ⁇ antibody or ⁇ -binding fragments thereof and their use in the treatment of abnormal accumulation or deposition of ⁇ in the central nervous system, mild cognitive impairment, and ⁇ -associated disorders such as Alzheimer's disease.
  • the disclosure features a pharmaceutical composition
  • a pharmaceutical composition comprising an anti- ⁇ antibody or ⁇ -binding fragment thereof and arginine hydrochloride (Arg.HCl).
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), the VH and VL comprising the CDRs of ⁇ 037.
  • VH immunoglobulin heavy chain variable domain
  • VL immunoglobulin light chain variable domain
  • the six CDRs of ⁇ 037 comprise or consist of the ammo acid sequences set forth in SEQ ID NO: l; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6.
  • the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml. In other embodiments, the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a
  • the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a concentration of 150 mg/ml. In certain embodiments, the composition comprises the anti- ⁇ antibody or ⁇ - binding fragment thereof at a concentration of 100 mg/ml. In some embodiments, the composition comprises Arg.HCl at a concentration of 50 mM to 250 mM. In other embodiments, the composition comprises Arg.HCl at a concentration of 75 mM to 175 mM. In certain embodiments, the composition comprises Arg.HCl at a concentration of 150 mM.
  • the composition further comprises Polysorbate-80 (PS80).
  • PS80 Polysorbate-80
  • the composition comprises PS80 at a concentration of 0.01% to 0.1%.
  • the composition comprises PS80 at a concentration of 0.03% to 0.08%.
  • the composition comprises PS80 at a concentration of 0.05%.
  • the composition further comprises a buffer selected from the group consisting of histidine, acetate, succinate, and citrate.
  • the buffer is histidine.
  • the buffer is acetate.
  • the buffer is succinate.
  • the buffer is citrate.
  • the composition comprises histidine, acetate, succinate, or citrate at a concentration of 10 mM to 30 mM.
  • the composition comprises histidine, acetate, succinate, or citrate at a concentration of 20 mM.
  • the composition comprises histidine at a concentration of 10 mM to 30 mM.
  • the composition comprises histidine at a concentration of 20 mM.
  • the composition further comprises methionine.
  • the composition comprises methionine at a concentration of 0.01 mM to 150 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 125 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 100 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 75 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 50 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 20 mM.
  • the composition comprises methionine at a concentration of 5 mM to 15 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 50 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 75 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 100 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 125 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 150 mM. In certain embodiments, the composition comprises methionine at a concentration of 10 mM.
  • the composition comprises methionine at a concentration of 50 mM. In certain embodiments, the composition comprises methionine at a concentration of 75 mM. In certain embodiments, the composition comprises methionine at a concentration of 100 mM. In certain embodiments, the composition comprises methionine at a concentration of 125 mM. In certain embodiments,
  • the composition comprises methionine at a concentration of 150 mM.
  • the composition further comprises sucrose. In some embodiments, the composition comprises sucrose at a concentration of 0.01% to 5%. In other embodiments, the composition comprises sucrose at a concentration of 1% to 4%. In certain embodiments, the composition comprises sucrose at a concentration of 3%.
  • the composition has a pH of 5.2 to 6.2. In certain embodiments, the composition has a pH of 5.2 to 6.2. In certain
  • the composition has a pH of 5.2 to 6.0. In certain embodiments, the composition has a pH of 5.3 to 5.7. In other embodiments, the composition has a pH of 5.5.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml; Arg.HCl at a concentration of 50 mM to 200 mM; methionine at a concentration of 0 mM to 20 mM; histidine at a concentration of 10 mM to 30 mM; PS80 at a concentration of 0.01% to 0.1%; and sucrose at a concentration of 0 to 3%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 150 mg/ml; Arg.HCl at a concentration of 150 mM; methionine at a concentration of 10 mM; histidine at a concentration of 20 mM; and PS 80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 100 mg/ml; Arg.HCl at a concentration of 1 0 mM; methionine at a concentration of 10 mM; histidine at a concentration of 20 mM; and PS 80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the VH comprises or consists of a sequence at least 80% identical to SEQ ID NO:7 and the VL comprises or consists of a sequence at least 80% identical to SEQ ID NO: 8. In some embodiments, the VH comprises or consists of a sequence at least 90% identical to SEQ ID NO:7 and the VL comprises or consists of a sequence at least 90% identical to SEQ ID NO: 8. In some embodiments, the VH comprises or consists of the sequence of SEQ ID NO:7 and the VL comprises or consists of the sequence of SEQ ID NO: 8.
  • the anti- ⁇ antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain.
  • the heavy chain comprises or consists of a sequence at least 80% identical to SEQ ID NO: 9 and the light chain comprises or consists of a sequence at least 80% identical to SEQ ID NO: 10.
  • the heavy chain comprises or consists of a sequence at least 90% identical to SEQ ID NO: 9 and the light chain comprises or consists of a sequence at least 90% identical to SEQ ID NO: 10.
  • the heavy chain comprises or consists of the sequence of SEQ ID NO:9 and the light chain comprises or consists of the sequence of SEQ ID NO: 10.
  • the disclosure features a method of treating abnormal accumulation or deposition of ⁇ in the central nervous system in a human subject in need thereof.
  • the method comprises administering to the human subject a pharmaceutical composition described herein.
  • the disclosure features a method of treating mild cognitive impairment in a human subject in need thereof.
  • the method comprises administering to the human subject a pharmaceutical composition described herein.
  • the disclosure features a method of treating Alzheimer's disease in a human subject in need thereof.
  • the method comprises administering to the human subject a pharmaceutical composition described herein.
  • the pharmaceutical composition is administered subcutaneously to the human subject. In some embodiments, of these aspects, the pharmaceutical composition is administered intravenously to the human subject.
  • the disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising an anti- ⁇ antibody or ⁇ -binding fragment thereof, a thiol-containing antioxidant, and arginine hydrochloride (Arg.HCl).
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), the VH and VL comprising the CDRs of BIIB037.
  • VH immunoglobulin heavy chain variable domain
  • VL immunoglobulin light chain variable domain
  • the six CDRs of BIIB037 comprise or consist of the ammo acid sequences set forth in SEQ ID NO: l; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6.
  • the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml. In other embodiments, the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a
  • the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a concentration of 150 mg/ml. In certain embodiments, the composition comprises the anti- ⁇ antibody or ⁇ - binding fragment thereof at a concentration of 100 mg/ml.
  • the thiol-containing antioxidant in the composition is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine.
  • the thiol- containing antioxidant is GSH.
  • the thiol-containing antioxidant is GSSG.
  • the thiol-containing antioxidant is GSH and GSSG.
  • the thiol-containing antioxidant is at a concentration of 0.02 mM to 4 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 0.02 mM to 2 mM.
  • the thiol-containing antioxidant is at a concentration of 0.2 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 0.4 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 1 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 2 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 4 mM. In certain instances, the thiol-containing antioxidant in the composition is GSH at a
  • the thiol-containing antioxidant in the composition is GSH at a concentration of 4 mM and GSSG at a concentration of 2 mM. In certain instances, the thiol-containing antioxidant in the composition is GSH at a concentration of 2 mM and GSSG at a concentration of 1 mM. In certain instances, the thiol-containing antioxidant in the composition is cysteine at a concentration of 0.4 mM and cystine at a concentration of 0.2 mM.
  • the composition comprises Arg.HCl at a concentration of 50 mM to 250 mM. In other embodiments, the composition comprises Arg.HCl at a concentration of 75 mM to 175 mM. In certain embodiments, the composition comprises Arg.HCl at a concentration of 150 mM. In some embodiments, the composition further comprises Polysorbate-80 (PS80). In some embodiments, the composition comprises PS80 at a concentration of 0.01% to 0.1%. In other embodiments, the composition comprises PS80 at a concentration of 0.03% to 0.08%. In certain embodiments, the composition comprises PS80 at a concentration of 0.05%.
  • PS80 Polysorbate-80
  • the composition further comprises a buffer selected from the group consisting of histidine, acetate, succinate, and citrate.
  • the buffer is histidine.
  • the buffer is acetate.
  • the buffer is succinate.
  • the buffer is citrate.
  • the composition comprises histidine, acetate, succinate, or citrate at a concentration of 10 mM to 30 mM.
  • the composition comprises histidine, acetate, succinate, or citrate at a concentration of 20 mM.
  • the composition comprises histidine at a concentration of 10 mM to 30 mM.
  • the composition comprises histidine at a concentration of 20 mM.
  • the composition further comprises sucrose. In some embodiments, the composition comprises sucrose at a concentration of 0.01% to 5%. In other embodiments, the composition comprises sucrose at a concentration of 1% to 4%. In certain embodiments, the composition comprises sucrose at a concentration of 3%.
  • the composition further comprises methionine.
  • the composition comprises methionine at a concentration of 0.01 mM to 150 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 125 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 100 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 75 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 50 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 20 mM.
  • the composition comprises methionine at a concentration of 5 mM to 15 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 50 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 75 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 100 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 125 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 150 mM. In certain embodiments, the composition comprises methionine at a concentration of 10 mM.
  • the composition comprises methionine at a concentration of 50 mM. In certain embodiments, the composition comprises methionine at a concentration of 75 mM. In certain embodiments, the composition comprises methionine at a concentration of 100 mM. In certain embodiments, the composition comprises methionine at a concentration of 125 mM. In certain embodiments,
  • the composition comprises methionine at a concentration of 150 mM. In some embodiments, the composition has a pH of 5.2 to 6.2. In certain embodiments, the composition has a pH of 5.2 to 6.0. In certain embodiments, the composition has a pH of 5.3 to 5.7. In other embodiments, the composition has a pH of 5.5.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; Arg.HCl at a concentration of 50 mM to 200 mM; histidine at a concentration of 10 mM to 30 mM; PS80 at a concentration of 0.01% to 0.1%; and sucrose at a concentration of 0 to 3%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine.
  • the thiol-containing antioxidant is GSH.
  • the thiol-containing antioxidant is GSSG.
  • the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 150 mg/ml; Arg.HCl at a concentration of 150 mM; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; histidine at a concentration of 20 mM; and PS 80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 100 mg/ml; Arg.HCl at a concentration of 150 mM; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; histidine at a concentration of 20 mM; and PS80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the VH comprises or consists of a sequence at least 80% identical to SEQ ID NO:7 and the VL comprises or consists of a sequence at least 80% identical to SEQ ID NO: 8. In some embodiments, the VH comprises or consists of a sequence at least 90% identical to SEQ ID NO:7 and the VL comprises or consists of a sequence at least 90% identical to SEQ ID NO: 8. In some embodiments, the VH comprises or consists of the sequence of SEQ ID NO:7 and the VL comprises or consists of the sequence of SEQ ID NO: 8.
  • the anti- ⁇ antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain.
  • the heavy chain comprises or consists of a sequence at least 80% identical to SEQ ID NO: 9 and the light chain comprises or consists of a sequence at least 80% identical to SEQ ID NO: 10.
  • the heavy chain comprises or consists of a sequence at least 90% identical to SEQ ID NO: 9 and the light chain comprises or consists of a sequence at least 90% identical to SEQ ID NO: 10.
  • the heavy chain comprises or consists of the sequence of SEQ ID NO:9 and the light chain comprises or consists of the sequence of SEQ ID NO: 10.
  • the disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising an anti- ⁇ antibody or ⁇ -binding fragment thereof, a thiol-containing antioxidant, methionine, and arginine hydrochloride (Arg.HCl).
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), the VH and VL comprising the CDRs of BIIB037.
  • the six CDRs of BIIB037 comprise or consist of the amino acid sequences set forth in SEQ ID NO: l; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6.
  • the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml. In other embodiments, the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a
  • the composition comprises the anti- ⁇ antibody or ⁇ -binding fragment thereof at a concentration of 150 mg/ml. In certain embodiments, the composition comprises the anti- ⁇ antibody or ⁇ - binding fragment thereof at a concentration of 100 mg/ml.
  • the thiol-containing antioxidant in the composition is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine.
  • the thiol- containing antioxidant is GSH.
  • the thiol-containing antioxidant is GSSG.
  • the thiol-containing antioxidant is GSH and GSSG.
  • the thiol-containing antioxidant is at a concentration of 0.02 mM to 4 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 0.02 mM to 2 mM.
  • the thiol-containing antioxidant is at a concentration of 0.2 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 0.4 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 1 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 2 mM. In certain embodiments, the thiol-containing antioxidant is at a concentration of 4 mM. In certain instances, the thiol-containing antioxidant in the composition is GSH at a
  • the thiol-containing antioxidant in the composition is GSH at a concentration of 4 mM and GSSG at a concentration of 2 mM. In certain instances, the thiol-containing antioxidant in the composition is GSH at a concentration of 2 mM and GSSG at a concentration of 1 mM. In certain instances, the thiol-containing antioxidant in the composition is cysteine at a concentration of 0.4 mM and cystine at a concentration of 0.2 mM.
  • the composition comprises methionine at a concentration of 0.01 mM to 150 mM. In some embodiments, the composition comprises methionine at a concentration of 0.01 mM to 125 mM. In some embodiments, the composition comprises methionine at a concentration of 0.01 mM to 100 mM. In some embodiments, the composition comprises methionine at a concentration of 0.01 mM to 75 mM. In some embodiments, the composition comprises methionine at a concentration of 0.01 mM to 50 mM. In some embodiments, the composition comprises methionine at a concentration of 0.01 mM to 20 mM.
  • the composition comprises methionine at a concentration of 5 mM to 15 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 50 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 75 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 100 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 125 mM. In other embodiments, the composition comprises methionine at a concentration of 5 mM to 150 mM. In certain embodiments, the composition comprises methionine at a concentration of 10 mM.
  • the composition comprises methionine at a concentration of 50 mM. In certain embodiments, the composition comprises methionine at a concentration of 75 mM. In certain embodiments, the composition comprises methionine at a concentration of 100 mM. In certain embodiments, the composition comprises methionine at a
  • the composition comprises methionine at a concentration of 150 mM.
  • the composition comprises Arg.HCl at a concentration of 50 mM to 250 mM. In other embodiments, the composition comprises Arg.HCl at a concentration of 75 mM to 175 mM. In certain embodiments, the composition comprises Arg.HCl at a concentration of 150 mM.
  • the composition further comprises Polysorbate-80 (PS80).
  • PS80 Polysorbate-80
  • the composition comprises PS80 at a concentration of 0.01% to 0.1%.
  • the composition comprises PS80 at a concentration of 0.03% to 0.08%.
  • the composition comprises PS80 at a concentration of 0.05%.
  • the composition further comprises a buffer selected from the group consisting of histidine, acetate, succinate, and citrate.
  • the buffer is histidine.
  • the buffer is acetate.
  • the buffer is succinate.
  • the buffer is citrate.
  • the composition comprises histidine, acetate, succinate, or citrate at a concentration of 10 mM to 30 mM.
  • the composition comprises histidine, acetate, succinate, or citrate at a concentration of 20 mM.
  • the composition comprises histidine at a concentration of 10 mM to 30 mM.
  • the composition comprises histidine at a concentration of 20 mM.
  • the composition further comprises sucrose.
  • the composition comprises sucrose at a concentration of 0.01% to 5%.
  • the composition comprises sucrose at a concentration of 1% to 4%.
  • the composition comprises sucrose at a concentration of 3%.
  • the composition has a pH of 5.2 to 6.2.
  • the composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; methionine at a concentration of 5 mM to 150 mM; Arg.HCl at a concentration of 50 mM to 200 mM; histidine at a concentration of 10 mM to 30 mM; PS80 at a concentration of 0.01% to 0.1%; and sucrose at a concentration of 0 to 3%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7. In other embodiments, the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 150 mg/ml; Arg.HCl at a concentration of 150 mM; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; methionine at a concentration of 10 mM; histidine at a concentration of 20 mM; and PS80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 150 mg/ml; Arg.HCl at a concentration of 150 mM; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; methionine at a concentration of 150 mM; histidine at a concentration of 20 mM; and PS80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 100 mg/ml; Arg.HCl at a concentration of 150 mM; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; methionine at a concentration of 10 mM; histidine at a concentration of 20 mM; and PS80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the pharmaceutical composition comprises the anti- ⁇ antibody or the ⁇ -binding fragment thereof at a concentration of 100 mg/ml; Arg.HCl at a concentration of 150 mM; a thiol-containing antioxidant at a concentration of 0.02 mM to 4 mM; methionine at a concentration of 150 mM; histidine at a concentration of 20 mM; and PS80 at a concentration of 0.05%.
  • this composition has a pH of 5.2 to 6.2.
  • this composition has a pH of 5.2 to 6.0.
  • the composition has a pH of 5.3 to 5.7.
  • the composition has a pH of 5.5.
  • the thiol-containing antioxidant is selected from the group consisting of GSH, GSSG, the combination of GSH and GSSG, cystine, cysteine, and the combination of cysteine and cystine. In some instances, the thiol-containing antioxidant is GSH. In some instances, the thiol-containing antioxidant is GSSG. In some instances, the thiol-containing antioxidant is the combination of GSH and GSSG.
  • the VH comprises or consists of a sequence at least 80% identical to SEQ ID NO:7 and the VL comprises or consists of a sequence at least 80% identical to SEQ ID NO: 8. In some embodiments, the VH comprises or consists of a sequence at least 90% identical to SEQ ID NO:7 and the VL comprises or consists of a sequence at least 90% identical to SEQ ID NO: 8. In some embodiments, the VH comprises or consists of the sequence of SEQ ID NO:7 and the VL comprises or consists of the sequence of SEQ ID NO: 8.
  • the anti- ⁇ antibody comprises an immunoglobulin heavy chain and an immunoglobulin light chain.
  • the heavy chain comprises or consists of a sequence at least 80% identical to SEQ ID NO: 9 and the light chain comprises or consists of a sequence at least 80% identical to SEQ ID NO: 10.
  • the heavy chain comprises or consists of a sequence at least 90% identical to SEQ ID NO: 9 and the light chain comprises or consists of a sequence at least 90% identical to SEQ ID NO: 10.
  • the heavy chain comprises or consists of the sequence of SEQ ID NO:9 and the light chain comprises or consists of the sequence of SEQ ID NO: 10.
  • the disclosure features a method of treating abnormal accumulation or deposition of ⁇ in the central nervous system in a human subject in need thereof.
  • the method comprises administering to the human subject a pharmaceutical composition described herein.
  • the disclosure features a method of treating mild cognitive impairment in a human subject in need thereof.
  • the method comprises administering to the human subject a pharmaceutical composition described herein.
  • the disclosure features a method of treating Alzheimer's disease in a human subject in need thereof.
  • the method comprises administering to the human subject a pharmaceutical composition described herein.
  • the pharmaceutical composition is administered subcutaneously to the human subject. In some embodiments, of these aspects, the pharmaceutical composition is administered intravenously to the human subject.
  • FIG. 1 is a bar graph depicting the %HMW for the indicated formulations stored at 40°C over 4 weeks.
  • FIG. 2 is a graph showing the %HMW for the indicated formulations stored at 40°C for 6 weeks.
  • FIG. 3 is a graph showing the %HMW trends at vary ing pH when stored at 25°C + 60% relative humidify.
  • FIG. 4 is a graph showing the %HMW trends for varying excipients when stored at 25°C + 60% relative humidity.
  • FIG. 5 is a bar graph showing the viscosity at 20°C for formulations.
  • FIG. 6 is a bar graph depicting the %HMW results for polysorbate-80 formulations after 72 hours at room temperature.
  • FIG. 7 is a graph showing the effect of the combination of GSH and GSSG on the stability of Aducanumab formulations at 25°C and 60% relative humidity.
  • FIG. 8 is a graph showing the effect of the combination of Cysteine and Cystine on the stability of Aducanumab formulations at 25°C and 60% relative humidity.
  • FIG. 9 is a graph showing that the reduced form of a thiol-containing excipient has the same impact on stability at 25°C and 60% relative humidity as the redox pair.
  • FIG. 10 is a graph illustrating that methionine provides limited benefit when combined with GSH on the stability of Aducanumab formulations at 25°C and 60% relative humidity.
  • FIG. 11 is a pair of graphs showing the effect of different antibody concentrations and GSH on stability at 25°C and 60% relative humidity.
  • FIG. 12 is a pair of graphs showing that even low concentrations of GSH can improve HMW stability.
  • FIG. 13 is a graph showing that GSH at 4 mM has the same impact on HMW reduction as GSH from 0.5 mM to 2 mM.
  • FIG. 14 is a pair of graphs showing the effect of increasing methionine on HMW levels at 25°C (top) and 40°C (bottom).
  • compositions containing anti- ⁇ antibodies and ⁇ -binding fragments thereof and their use in the treatment of abnormal accumulation or deposition of ⁇ in the central nervous system, mild cognitive impairment, and ⁇ - associated disorders (e.g., Alzheimer's disease).
  • Amyloid beta ( ⁇ or Abeta)
  • the ⁇ peptide is an important risk factor and has a central role in the onset and progression of Alzheimer's disease. ⁇ is produced in normal individuals, but under some circumstances, this molecule aggregates leading to disease progression.
  • ⁇ denotes peptides of 36 to 43 amino acids that are involved in forming amyloid plaques found in the brains of patients with Alzheimer's disease. Similar plaques appear in some variants of Lewy body dementia and in inclusion body myositis. ⁇ also forms the aggregates that coat cerebral blood vessels in cerebral amyloid angiopathy.
  • the ⁇ peptides are formed by cleavage of the amyloid precursor protein (APP) by the enzymes beta secretase and gamma secretase.
  • APP amyloid precursor protein
  • ⁇ molecules can aggregate to form flexible soluble oligomers which may exist in several forms.
  • the amino acid sequence of human Amyloid ⁇ Peptide (1-40) is provided below:
  • Soluble oligomeric forms of the ⁇ peptide are thought to be causative agents in the development of Alzheimer's disease.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof used in the compositions and methods described herein comprises the three heavy chain variable domain complementarity determining regions (CDRs) of an antibody referred to as
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises the three light chain variable domain CDRs of BIIB037. In still other embodiments, the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises the three heavy chain variable domain CDRs and the three light chain variable domain CDRs of BIIB037.
  • BIIB037 is a fully human antibody comprising a glycosylated human IgGl heavy chain and a human kappa light chain. BIIB037 consists of the mature heavy chain amino acid sequence depicted in SEQ ID NO:9 and the mature light chain amino acid sequence depicted in SEQ ID NO: 10.
  • VH and VL of BIIB037 have amino acid sequences that are identical to the amino acid sequence of the VH and VL of antibody NI-101.12F6A described in US Patent No. 8,906,367 (see, Tables 2-4; incorporated by reference in its entirety herein).
  • antibody BIIB037 has an antigen binding domain comprising VH and VL variable regions depicted in Table 1 (VH) and Table 2 (VL), corresponding complementarity determining regions (CDRs) depicted in Table 3, and heavy and light chains depicted in Table 4 (H) and Table 5 (L)
  • VL CDRs Amino acid sequences of the VL region of anti- ⁇ antibody BIIB037 (VL CDRs (Kabat definition) underlined).
  • Variable light chain sequence (kappa or lambda)
  • Amino acid sequences of the heavy chain of anti- ⁇ antibody BIIB037 (heavy chain CDRs (Kabat definition) underlined).
  • amino acid sequence of the mature light chain of BIIB037 is provided in Table 5 below.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises of a VH CDR1 compnsing or consisting of the amino acid sequence set forth in SEQ ID NO. : l, a VH CDR2 compnsing or consisting of the amino acid sequence set forth in SEQ ID NO. :2; and a VH CDR3 comprising or consisting of the amino acid sequence set forth in SEQ ID NO.: 3.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a VL CDR1 comprising or consisting of the amino acid sequence set forth in SEQ ID NO.:4, a VL CDR2 comprising or consisting of the amino acid sequence set forth in SEQ ID NO. :5; and a VL CDR3 comprising or consisting of the amino acid sequence set forth in SEQ ID NO : 6.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises the CDRs comprising or consisting of the amino acid sequences set forth in SEQ ID NOs. : l to 6.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a VH comprising or consisting of the amino acid sequence set forth in SEQ ID NO:7.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof selectively binds to a peptide comprising or consisting of amino acids 1-16 of human ⁇ and comprises a VH domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VH domain of BIIB037 (SEQ ID NO:7), or differs at least at 1 to 5 amino acid residues, but at fewer than 40, 30, 20, 15, or 10, residues, from SEQ ID NO:7.
  • these anti- ⁇ antibody or ⁇ -binding fragments thereof selectively binds to a peptide comprising or consisting of amino acids 3-6 of human ⁇ .
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a VL comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 8.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof selectively binds to a peptide comprising or consisting of amino acids 1-16 of human ⁇ and comprises a VL domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VL domain of BIIB037 (SEQ ID NO:8), or differs at least at 1 to 5 amino acid residues, but at fewer than 40, 30, 20, 15, or 10, residues, from SEQ ID NO: 8.
  • these anti- ⁇ antibody or ⁇ -binding fragments thereof selectively binds to a peptide comprising or consisting of amino acids 3-6 of human ⁇ .
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a VH having the amino acid sequence set forth in SEQ ID NO:7 and a VL having the amino acid sequence set forth in SEQ ID NO: 8.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof selectively binds to a peptide comprising or consisting of amino acids 1-16 of human ⁇ and comprises (i) a VH domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VH domain of BIIB037 (SEQ ID NO:7), and (ii) a VL domain that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of the VL domain of BIIB037 (SEQ ID NO:7), and
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a heavy chain (HC) having the amino acid sequence set forth in SEQ ID NO:9.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof selectively binds to a peptide comprising or consisting of amino acids 1-16 of human ⁇ and comprises a HC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:9, or differs at least at 1 to 5 amino acid residues, but at fewer than 40, 30, 20, 15, or 10, residues, from SEQ ID NO:9.
  • these anti- ⁇ antibody or ⁇ -binding fragments thereof selectively binds to a peptide comprising or consisting of amino acids 3-6 of human ⁇ .
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a light chain (LC) having the amino acid sequence set forth in SEQ ID NO: 10.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof selectively binds to a peptide comprising or consisting of amino acids 1-16 of human ⁇ and comprises a LC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO: 10, or differs at least at 1 to 5 amino acid residues, but at fewer than 40, 30, 20, 15, or 10, residues, from SEQ ID NO: 10.
  • these anti- ⁇ antibody or ⁇ -binding fragments thereof selectively binds to a peptide comprising or consisting of amino acids 3-6 of human ⁇ .
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof comprises a HC having the amino acid sequence set forth in SEQ ID NO:9 and a LC having the amino acid sequence set forth in SEQ ID NO: 10.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof selectively binds to a peptide comprising or consisting of amino acids 1-16 of human ⁇ and comprises (i) a HC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:9, or differs at least at 1 to 5 amino acid residues, but at fewer than 40, 30, 20, 15, or 10, residues, from SEQ ID NO: 9; and (ii) a LC that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
  • the anti- ⁇ antibody is an IgG antibody.
  • the anti- ⁇ antibody has heavy chain constant region chosen from, e.g., IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE.
  • the anti- ⁇ antibody is of the human IgGl isotype.
  • the anti- ⁇ antibody is of the human IgG2 isotype.
  • the anti- ⁇ antibody is of the human IgG3 isotype.
  • the anti- ⁇ antibody is of the human IgG4 isotype.
  • the antibody has a light chain constant region chosen from, e.g., a human kappa or human lambda light chain.
  • the anti- ⁇ antibody is a human IgGl/human kappa antibody.
  • the heavy chain constant region is human or a modified form of a human constant region.
  • the human constant region may include at least 1 and up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 substitutions.
  • the modified human Fc region is a modified human IgGl Fc region.
  • the constant region of an anti- ⁇ antibody is modified by mutation of one or more amino acid residues to impart a desired functional property (e.g., altered effector function or half-life, reduced glycosylation).
  • the N-linked glycosylation site may be substituted to prevent or reduce N-linked glycosylation of Fc region (e.g., human IgGl Fc region).
  • the anti- ⁇ antibody is a full-length (whole) antibody or substantially full-length.
  • the protein can include at least one, and preferably two, complete heavy chains, and at least one, and preferably two, complete light chains.
  • the anti- ⁇ antibody is a ⁇ -binding fragment.
  • the ⁇ - binding fragment is a Fab, a Fab', an F(ab')2, a Facb, an Fv, a single chain Fv (scFv), a sc(Fv)2, or a diabody.
  • Antibodies such as BIIB037, or ⁇ -binding fragments thereof can be made, for example, by preparing and expressing synthetic genes that encode the recited amino acid sequences or by mutating human germline genes to provide a gene that encodes the recited amino acid sequences. Moreover, this antibody and other anti- ⁇ antibodies can be produced, e.g., using one or more of the following methods.
  • Anti- ⁇ antibodies or ⁇ -binding fragments may be produced in bacterial or eukaryotic cells. Some antibodies, e.g., Fab's, can be produced in bacterial cells, e.g., E. coli cells. Antibodies can also be produced in eukaryotic cells such as transformed cell lines (e.g., CHO, 293E, COS). In addition, antibodies (e.g., scFv's) can be expressed in a yeast cell such as Pichia (see, e.g., Powers et al., J Immunol Methods . 251 : 123-35 (2001)), Hanseula, or Saccharomyces.
  • a yeast cell such as Pichia (see, e.g., Powers et al., J Immunol Methods . 251 : 123-35 (2001)), Hanseula, or Saccharomyces.
  • a polynucleotide encoding the antibody is constructed, introduced into an expression vector, and then expressed in suitable host cells.
  • Polynucleotides encoding an anti- ⁇ antibody comprising the VH and/or VL, HC and/or LC of the ⁇ antibodies described herein would be readily envisioned by the ordinarily skilled artisan. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody.
  • the expression vector should have characteristics that permit amplification of the vector in the bacterial cells. Additionally, when E. coli such as JM109, DH5a, HBlOl, or XL 1 -Blue is used as a host, the vector must have a promoter, for example, a lacZ promoter (Ward et al, 341 :544-546 (1989), araB promoter (Better et al, Science, 240: 1041-1043 (1988)), or T7 promoter that can allow efficient expression in E. coli.
  • a promoter for example, a lacZ promoter (Ward et al, 341 :544-546 (1989), araB promoter (Better et al, Science, 240: 1041-1043 (1988)
  • T7 promoter that can allow efficient expression in E. coli.
  • Such vectors include, for example, M13-series vectors, pUC-series vectors, pBR322, pBluescript, pCR-Script, pGEX-5X-l (Pharmacia), "QIAexpress system” (QIAGEN), pEGFP, and pET (when this expression vector is used, the host is preferably BL21 expressing T7 RNA polymerase).
  • the expression vector may contain a signal sequence for antibody secretion.
  • the pelB signal sequence Lei et al, J. BacterioL, 169:4379 (1987)
  • calcium chloride methods or electroporation methods may be used to introduce the expression vector into the bacterial cell.
  • the expression vector includes a promoter necessary for expression in these cells, for example, an SV40 promoter (Mulligan et al., Nature, 277: 108 (1979)), MMLV-LTR promoter, EF la promoter (Mizushima al, Nucleic Acids Res., 18:5322 (1990)), or CMV promoter.
  • SV40 promoter Mulligan et al., Nature, 277: 108 (1979)
  • MMLV-LTR promoter MMLV-LTR promoter
  • EF la promoter EF la promoter
  • CMV promoter CMV promoter
  • the recombinant expression vectors may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes.
  • the selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017).
  • typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin, or methotrexate, on a host cell into which the vector has been introduced.
  • examples of vectors with selectable markers include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
  • antibodies are produced in mammalian cells.
  • exemplary mammalian host cells for expressing an antibody include Chinese Hamster Ovary (CHO cells) (including dhj CHO cells, described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp (1982) Mo/. Biol.
  • human embryonic kidney 293 cells e.g., 293, 293E, 293T
  • COS cells e.g., NIH3T3 cells
  • lymphocytic cell lines e.g., NS0 myeloma cells and SP2 cells
  • a cell from a transgenic animal e.g., a transgenic mammal.
  • the cell is a mammary epithelial cell.
  • a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain of an anti- ⁇ antibody is introduced into dhfr CHO cells by calcium phosphate-mediated transfection.
  • the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements (e.g., derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/ AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of the genes.
  • enhancer/promoter regulatory elements e.g., derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/ AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element
  • the recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.
  • the selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and the antibody is recovered from the culture medium.
  • Antibodies can also be produced by a transgenic animal.
  • U.S. Pat. No. 5,849,992 describes a method of expressing an antibody in the mammary gland of a transgenic mammal.
  • a transgene is constructed that includes a milk-specific promoter and nucleic acids encoding the antibody of interest and a signal sequence for secretion.
  • the milk produced by females of such transgenic mammals includes, secreted-therein, the antibody of interest.
  • the antibody can be purified from the milk, or for some applications, used directly. Animals are also provided comprising one or more of the nucleic acids described herein.
  • the antibodies of the present disclosure can be isolated from inside or outside (such as medium) of the host cell and purified as substantially pure and homogenous antibodies. Methods for isolation and purification commonly used for antibody purification may be used for the isolation and purification of antibodies, and are not limited to any particular method. Antibodies may be isolated and purified by appropriately selecting and combining, for example, column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel
  • Chromatography includes, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, and adsorption
  • Chromatography can be carried out using liquid phase chromatography such as HPLC and FPLC
  • Columns used for affinity chromatography include protein A column and protein G column. Examples of columns using protein A column include Hyper D, POROS, and Sepharose FF (GE Healthcare Biosciences).
  • the present disclosure also includes antibodies that are highly purified using these purification methods.
  • compositions comprising the anti- ⁇ antibodies or ⁇ -binding fragments thereof described herein.
  • the anti- ⁇ antibody compositions comprises an anti- ⁇ antibody or ⁇ -binding fragment thereof comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL), wherein the VH comprises the H-CDRs and the VL comprises the L-CDRs of BIIB037.
  • VH immunoglobulin heavy chain variable domain
  • VL immunoglobulin light chain variable domain
  • the heavy chain CDRs comprise or consist of the amino acid sequences set forth in SEQ ID NO: 1, SEQ ID NO:2, and SEQ ID NO:3; and the light chain CDRs (L-CDRs) comprise or consist of the amino acid sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
  • the anti- ⁇ antibody compositions comprises an anti- ⁇ antibody or ⁇ - binding fragment thereof comprising (i) a VH comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:7; and (ii) a VL comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 8.
  • the anti- ⁇ antibody compositions comprises an anti- ⁇ antibody comprising (i) a heavy chain comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 9; and (ii) a light chain comprising or consisting of an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 10.
  • the anti- ⁇ antibodies selectively bind to a peptide comprising or consisting of amino acids 1-16 of human ⁇ . In some embodiments, the anti- ⁇ antibodies selectively bind to a peptide comprising or consisting of amino acids 3-6 of human ⁇ .
  • these compositions are high concentration anti- ⁇ antibody compositions.
  • high concentration anti- ⁇ antibody composition is meant a
  • composition comprising anti- ⁇ antibodies or ⁇ -binding fragments thereof at a
  • the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 50 mg/ml to 250 mg/ml. In certain instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 50 mg/ml to 225 mg/ml. In other instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 75 mg/ml to 225 mg/ml. In other instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 75 mg/ml to 165 mg/ml.
  • the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 100 mg/ml to 225 mg/ml. In yet other instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 125 mg/ml to 225 mg/ml. In other instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 125 mg/ml to 175 mg/ml. In certain instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 240 mg/ml.
  • the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ - binding fragments thereof at a concentration of 225 mg/ml. In certain instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 200 mg/ml. In certain instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 175 mg/ml. In certain instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 150 mg/ml. In other instances, the anti- ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 125 mg/ml. In some instances, the anti ⁇ antibody composition comprises anti- ⁇ antibodies or ⁇ -binding fragments thereof at a concentration of 100 mg/ml.
  • a composition comprising an anti- ⁇ antibody or ⁇ -binding fragment thereof described herein may be in any one of a variety of forms. These include, for example, liquid solutions (e.g., injectable and infusible solutions), dispersions, or suspensions. The preferred form can depend on the intended mode of administration and therapeutic application.
  • a pharmaceutical composition described herein is in the form of a sterile injectable or infusible solution.
  • Sterile injectable solutions can be prepared by incorporating an antibody described herein in the required amount with one or a combination of ingredients, followed by filtered sterilization.
  • dispersions are prepared by incorporating an antibody described herein into a sterile vehicle that contains a basic dispersion medium and the required other ingredients.
  • an exemplary method of preparation is vacuum dry ing and freeze drying that yields a powder of an antibody described herein plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants.
  • the anti- ⁇ antibody compositions may additionally comprise one or more excipients.
  • the excipient lowers/reduces the aggregation and/or viscosity of the antibody in the composition compared to aggregation and/or viscosity of the antibody in the pharmaceutical composition without that excipient.
  • such an excipient is arginine.
  • the excipient is L-arginine hydrochloride.
  • Arginine e.g., L-arginine hydrochloride
  • Arginine hydrochloride can be included in the composition at a concentration of 40 mM to 260 mM, 50 mM to 250 mM, 50 mM to 200 mM, 50 mM to 150 mM, 50 mM to 125 mM, 50 mM to 100 mM, 75 mM to 250 mM, 75 mM to 200 mM, 75 mM to 150 mM, or 75 mM to 100 mM.
  • arginine e.g., Arg.HCl
  • arginine e.g., Arg.HCl
  • arginine e.g., Arg.HCl
  • arginine hydrochloride can be included in the composition at a concentration of 80 mM, 100 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 220 mM, or 260 mM.
  • arginine e.g., arginine hydrochloride
  • arginine e.g., arginine hydrochloride
  • arginine hydrochloride can be included in the composition at a concentration of 100 mM.
  • arginine e.g., arginine hydrochloride
  • 150 mM e.g., 150 mM.
  • the anti- ⁇ antibody composition comprises sucrose at a concentration of 0.05% to 5%, 0.05% to 4%, 0.05% to 3%, 1% to 5 %, 1% to 4%, 1% to 3%, 2% to 5%, 2% to 4%, or 2% to 3%.
  • the anti- ⁇ antibody composition comprises sucrose at a concentration of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5%.
  • the anti- ⁇ antibody composition comprises sucrose at a concentration of 3%.
  • the anti- ⁇ antibody composition comprises sucrose at a concentration of 1%.
  • the anti- ⁇ antibody compositions comprise methionine.
  • methionine is included in the composition at a concentration from 0.5 mM to 150 mM.
  • methionine is included in the composition at a concentration from 0.5 mM to 25 mM.
  • methionine is included in the composition at a concentration from 5 mM to 150 mM.
  • methionine is included in the composition at a concentration of 5 mM, 10 mM, 15 mM, 20 mM or 25 mM, 50 mM, 75 mM, 100 mM, 125 mM, or 150 mM.
  • methionine is included in the composition at a concentration of 10 mM.
  • methionine is included in the composition at a concentration of 150 mM.
  • Antibody product manufacturing is a complex process that can involve several steps such as, e.g., drug substance and bulk formulation, filtration, shipping, pooling, filling, lyophilization, inspections, packaging, and storage. During these steps, antibodies may be subjected to many different forms of stresses, e.g., agitation, temperature, light exposure, and oxidation. These types of stresses can lead to denaturation and aggregation of the antibody, which compromise the product quality and can even lead to loss of a production batch.
  • the composition may include a polysorbate.
  • the composition comprises polysorbate-80 at a concentration of 0.01% to 0.5%, 0.01% to 0.1%, 0.01% to 0.09%, 0.01% to 0.08%, 0.01% to 0.07%, 0.01% to 0.06%, 0.01% to 0.05%, 0.01% to 0.04%, or 0.01% to 0.03%.
  • the composition comprises polysorbate-80 at a concentration of 0.02% to 0.08%. In some embodiments, the composition comprises polysorbate-80 at a concentration of 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, or 0.1%. In a particular embodiment, the composition comprises polysorbate-80 at a concentration of 0.05%.
  • the antibody composition comprises histidine as the buffering agent.
  • the composition comprises histidine at a concentration of 5 mM to 50 mM, 5 mM to 40 mM, 5 mM to 35 mM, 5 mM to 30 mM, 5 mM to 25 mM, 10 mM to 50 mM, 10 mM to 40 mM, 10 mM to 30 mM, 10 mM to 25 mM, 15 mM to 50 mM, 15 mM to 40 mM, 15 mM to 30 mM, or 15 mM to 25 mM.
  • the composition comprises histidine at a concentration of 5 mM to 35 mM. In certain embodiments, the composition comprises histidine at a concentration of 10 mM to 30 mM. In some embodiments, the composition comprises histidine at a concentration of 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, or 35 mM. In a particular embodiment, the composition comprises histidine at a concentration of 20 mM. In certain embodiments, the antibody composition comprises acetate as the buffering agent.
  • the composition comprises acetate at a concentration of 5 mM to 50 mM, 5 mM to 40 mM, 5 mM to 35 mM, 5 mM to 30 mM, 5 mM to 25 mM, 10 mM to 50 mM, 10 mM to 40 mM, 10 mM to 30 mM, 10 mM to 25 mM, 15 mM to 50 mM, 15 mM to 40 mM, 15 mM to 30 mM, or 15 mM to 25 mM.
  • the composition comprises acetate at a concentration of 5 mM to 50 mM, 5 mM to 40 mM, 5 mM to 35 mM, 5 mM to 30 mM, 5 mM to 25 mM, 10 mM to 50 mM, 10 mM to 40 mM, 10 mM to 30 mM, 10 mM to 25 mM, 15 mM to 50 mM
  • the composition comprises acetate at a concentration of 10 mM to 30 mM. In some embodiments, the composition comprises acetate at a concentration of 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, or 35 mM. In a particular embodiment, the composition comprises acetate at a concentration of 20 mM. In certain embodiments, the antibody composition comprises succinate as the buffering agent.
  • the composition comprises succinate at a concentration of 5 mM to 50 mM, 5 mM to 40 mM, 5 mM to 35 mM, 5 mM to 30 mM, 5 mM to 25 mM, 10 mM to 50 mM, 10 mM to 40 mM, 10 mM to 30 mM, 10 mM to 25 mM, 15 mM to 50 mM, 15 mM to 40 mM, 15 mM to 30 mM, or 15 mM to 25 mM.
  • the composition comprises succinate at a concentration of 5 mM to 35 mM.
  • the composition comprises succinate at a concentration of 10 mM to 30 mM. In some embodiments, the composition comprises succinate at a concentration of 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, or 35 mM. In a particular embodiment, the composition comprises succinate at a concentration of 20 mM. In certain embodiments, the antibody composition comprises citrate as the buffering agent.
  • the composition comprises citrate at a concentration of 5 mM to 50 mM, 5 mM to 40 mM, 5 mM to 35 mM, 5 mM to 30 mM, 5 mM to 25 mM, 10 mM to 50 mM, 10 mM to 40 mM, 10 mM to 30 mM, 10 mM to 25 mM, 15 mM to 50 mM, 15 mM to 40 mM, 15 mM to 30 mM, or 15 mM to 25 mM.
  • the composition comprises citrate at a concentration of 5 mM to 35 mM.
  • the composition comprises citrate at a concentration of 10 mM to 30 mM. In some embodiments, the composition comprises citrate at a concentration of 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, or 35 mM. In a particular embodiment, the composition comprises citrate at a concentration of 20 mM.
  • the pH of the antibody composition can be from 5.0 to 6.5. In certain cases, the pH of the antibody composition can be 5.2 to 6.2. In certain instances, the pH of the antibody composition is 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5. In a particular embodiment, the pH of the antibody composition is 5.5.
  • the ⁇ compositions comprise arginine (e.g., Arg. HC1). In other instances, the ⁇ compositions comprise arginine (e.g., Arg. HC1) and methionine.
  • the ⁇ compositions comprise L-arginine hydrochloride (e.g., 150 mM), methionine (e.g., 10 mM), histidine (e.g., 20 mM), and PS80 (e.g., 0.05%), and has a pH of 5.2 to 6.2.
  • the ⁇ compositions comprise L-arginine hydrochloride (e.g., 150 mM), methionine (e.g., 10 mM, 150 mM), histidine (e.g., 20 mM), and PS80 (e.g., 0.05%), and has a pH of 5.5.
  • the ⁇ compositions comprise L-arginine hydrochloride (e.g., 150 mM), methionine (e.g., 10 mM, 150 mM), histidine (e.g., 20 mM), PS80 (e.g., 0.05%), and sucrose (up to 3%), and has a pH of 5.2 to 6.2.
  • the ⁇ compositions comprise L-arginine hydrochloride, methionine, histidine, PS80, and sucrose, and has a pH of 5.5.
  • the anti- ⁇ antibody is present at a concentration of 100 mg/ml to 165 mg/ml. In one instance, the anti- ⁇ antibody is present at a concentration of 150 mg/ml. In one instance, the anti- ⁇ antibody is present at a concentration of 100 mg/ml.
  • the anti- ⁇ composition comprises a thiol-containing antioxidant (e.g., reduced glutathione (GSH), oxidized glutathione (GSSG), GSH + GSSG, cysteine, cystine, cysteine + cystine) at a concentration of 0.02 mM to 4 mM (e.g., 0.02, 0.03, 0.05, 0.06, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7.
  • a thiol-containing antioxidant e.g., reduced glutathione (GSH), oxidized glutathione (GSSG), GSH + GSSG, cysteine, cystine, cysteine + cystine
  • 0.02 mM to 4 mM e.g., 0.02,
  • the composition comprises GSH at a concentration of 0.4 mM. In some cases, the composition comprises GSSG at a concentration of 0.2 mM.
  • the composition comprises GSH at a concentration of 0.4 mM and GSSG at a concentration of 0.2 mM. In some cases, the composition comprises GSH at a concentration of 4 mM and GSSG at a concentration of 2 mM. In some cases, the composition comprises GSH at a concentration of 2 mM and GSSG at a concentration of 1 mM. In some cases, the composition comprises cysteine at a concentration of 0.4 mM. In some cases, the composition comprises cystine at a concentration of 0.2 mM. In some cases, the composition comprises cysteine at a concentration of 0.4 mM and cystine at a concentration of 0.2 mM.
  • the ⁇ compositions comprise arginine (e.g., Arg.HCl), a thiol-containing antioxidant, and methionine.
  • the ⁇ compositions comprise L-arginine hydrochloride (e.g., 150 mM), methionine (e.g., 10 mM), histidine (e.g., 20 mM), a thiol-containing antioxidant such as GSH, GSSG, GSH and GSSG, cysteine, cystine, or cysteine and cystine (e.g., 0.02 mM to 4 mM), and PS80 (e.g., 0.05%), and has a pH of 5.2 to 6.2.
  • L-arginine hydrochloride e.g., 150 mM
  • methionine e.g., 10 mM
  • histidine e.g., 20 mM
  • a thiol-containing antioxidant such as GSH, GSSG, GSH and GSSG, cysteine, cystine, or cysteine and cystine (e.g., 0.02 mM to 4 mM)
  • PS80 e.g
  • the ⁇ compositions comprise L-arginine hydrochloride (e.g., 150 mM), methionine (e.g., 10 mM, 150 mM), histidine (e.g., 20 mM), a thiol-containing antioxidant such as GSH, GSSG, GSH and GSSG, cysteine, cystine, or cysteine and cystine (e.g., 0.02 mM to 4 mM), and PS80 (e.g., 0.05%), and has a pH of 5.5.
  • L-arginine hydrochloride e.g., 150 mM
  • methionine e.g., 10 mM, 150 mM
  • histidine e.g., 20 mM
  • a thiol-containing antioxidant such as GSH, GSSG, GSH and GSSG, cysteine, cystine, or cysteine and cystine
  • PS80 e.g., 0.05%)
  • the ⁇ compositions comprise L-arginine hydrochloride (e.g., 150 mM), methionine (e.g., 10 mM, 150 mM), histidine (e.g., 20 mM), PS80 (e.g., 0.05%), a thiol-containing antioxidant such as GSH, GSSG, GSH and GSSG, cysteine, cystine, or cysteine and cystine (e.g., 0.02 mM to 4 mM), and sucrose (up to 3%), and has a pH of 5.2 to 6.2.
  • L-arginine hydrochloride e.g., 150 mM
  • methionine e.g., 10 mM, 150 mM
  • histidine e.g., 20 mM
  • PS80 e.g., 0.05%
  • a thiol-containing antioxidant such as GSH, GSSG, GSH and GSSG, cysteine, cystine, or
  • the ⁇ compositions comprise L-arginine hydrochloride, methionine, histidine, PS80, a thiol- containing antioxidant such as GSH, GSSG, GSH and GSSG, cy steine, cystine, or cysteine and cystine, and sucrose, and has a pH of 5.5.
  • the anti- ⁇ antibody is present at a concentration of 100 mg/ml to 165 mg/ml. In one instance, the anti- ⁇ antibody is present at a concentration of 150 mg/ml. In one instance, the anti- ⁇ antibody is present at a concentration of 100 mg/ml.
  • the composition (e.g., a pharmaceutical composition) comprises an anti- ⁇ antibody or a ⁇ -binding fragment thereof at a concentration of 50 mg/ml to 250 mg/ml, arginine (e.g.. L-arginine hydrochloride) at a concentration of 50 mM to 200 mM, methionine at a concentration of 1 mM to 150 mM (e.g., 1 mM to 20 mM);
  • arginine e.g.. L-arginine hydrochloride
  • methionine at a concentration of 1 mM to 150 mM (e.g., 1 mM to 20 mM)
  • polysorbate-80 at a concentration of 0.01% to 0.1%, histidine at a concentration of 10 mM to 30 mM, and sucrose at a concentration of 0% to 3%.
  • the composition has a pH of 5.2 to 6.2. In other cases, the composition has a pH of 5.2 to 6.0.
  • the anti- ⁇ antibody or a ⁇ -binding fragment thereof of the composition comprises a VH and a VL comprising the CDRs of BIIB037 (e.g., SEQ ID NOs.: 1, 2, 3, 4, 5, and 6).
  • the anti- ⁇ antibody or a ⁇ -binding fragment thereof of the composition comprises a VH and a VL comprising SEQ ID NOs: 7 and 8, respectively.
  • the anti- ⁇ antibody or a ⁇ -binding fragment thereof of the composition comprises a heavy chain and a light chain comprising SEQ ID NOs: 9 and 10, respectively.
  • the composition has a pH of 5.5 and comprises BIIB037 or a BIIB037-binding fragment thereof at a concentration of 150 mg/ml, L-arginine
  • the composition further comprises a thiol-containing antioxidant (e.g., GSH, GSSG, GSH + GSSG, cysteine, cystine, cysteine + cystine) at a concentration of 0.02 mM to 4 mM.
  • a thiol-containing antioxidant e.g., GSH, GSSG, GSH + GSSG, cysteine, cystine, cysteine + cystine
  • sucrose at a concentration of 0.01% to 3%.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof of the composition comprises a VH and a VL comprising the CDRs of BIIB037 (e.g., SEQ ID NOs. : 1, 2, 3, 4, 5, and 6).
  • the anti- ⁇ antibody or ⁇ - binding fragment thereof of the composition comprises a VH and a VL comprising SEQ ID NOs: 7 and 8, respectively.
  • the anti- ⁇ antibody or ⁇ -binding fragment thereof of the composition comprises a heavy chain and a light chain comprising SEQ ID NOs: 9 and 10, respectively.
  • the composition has a pH of 5.5 and comprises BIIB037 or a BIIB037-binding fragment thereof at a concentration of 150 mg/ml, L-arginine hy drochloride at a concentration of 150 mM, a thiol-containing antioxidant (e.g., GSH, GSSG, GSH + GSSG, cysteine, cystine, cysteine + cystine) at a concentration of 0.02 mM to 4 mM, polysorbate-80 at a concentration of 0.05%, and histidine at a concentration of 20 mM.
  • the thiol-containing antioxidant is GSH at a concentration of 0.4 mM.
  • the thiol-containing antioxidant is GSH at a concentration of 0.4 mM and GSSG at a concentration of 0.2 mM. In one embodiment, the thiol-containing antioxidant is GSH at a concentration of 4 mM and GSSG at a concentration of 2 mM. In one embodiment, the thiol-containing antioxidant is GSH at a concentration of 2 mM and GSSG at a concentration of 1 mM. In another embodiment, the thiol-containing antioxidant is cysteine at a concentration of 0.4 mM. In another embodiment, the thiol-containing antioxidant is cysteine at a concentration of 0.4 mM and cystine at a concentration of 0.2 mM.
  • BIIB037 recognizes aggregated forms of ⁇ , including plaques. In vitro
  • compositions disclosed herein are useful in treating abnormal accumulation or deposition of ⁇ in the central nervous system of a human subject in need thereof.
  • compositions disclosed herein are also useful in treating mild cognitive impairment in a human subject in need thereof.
  • the terms “treat”, “treating”, or “treatment” generally mean obtaining a desired pharmacological and/or physiological effect.
  • compositions disclosed herein are useful in treating AD in a human subject in need thereof. In other embodiments, the compositions disclosed herein are useful in preventing AD in a human subject in need thereof.
  • compositions disclosed herein can be used to: (a) prevent AD from occurring in a subject who may be predisposed to AD, but has not yet been diagnosed as having it; (b) inhibiting AD, e.g. arresting its development; (c) relieving AD, e.g. causing regression of AD; or (d) prolonging survival as compared to expected survival if not receiving treatment.
  • a human subject in need thereof is administered a therapeutically effective amount or dose of the anti- ⁇ antibody or ⁇ -binding fragment thereof.
  • a therapeutically effective amount refers to the amount of the antibody sufficient to ameliorate a symptom or condition associated with AD.
  • Therapeutic efficacy and toxicity of the antibody can be determined by standard pharmaceutical procedures.
  • the antibody is employed in an amount sufficient to restore normal behavior and/or cognitive properties in case of Alzheimer's disease, or at least delay or prevent the progression of AD in the patient.
  • the composition comprising the anti- ⁇ antibody or ⁇ - binding fragment thereof is administered intravenously to the human subject. In certain embodiments, the composition comprising the anti- ⁇ antibody or ⁇ -binding fragment thereof is administered subcutaneously to the human subject.
  • Example 1 pH and Buffer Screened for Optimal Formulation
  • Histidine buffer showed the lowest change in percentage high molecular weight species (% HMW) compared to Acetate, Succinate, and Citrate buffers.
  • Figure 3 shows the %HMW trends at varying pH when stored at 25°C + 60% relative humidity. The rate of increase of %HMW over time is consistent across this pH range.
  • Figure 4 shows the %HMW trends for varying excipients when stored at 25°C + 60% relative humidity. The rate of increase of %HMW is consistent whether the stabilizing excipient is 150mM L-Arginine HCl + lOmM Methionine, lOOmM L-Arginine HCl + lOmM Methionine, 150mM L-Arginine HCl without Methionine, or lOOmM L-Arginine HCl + 3% Sucrose.
  • Viscosities ⁇ 50cP are optimal for manufacturing processes and route of administration options.
  • the Arginine-based formulations provide consistently low viscosity ( ⁇ 20cP) at high protein concentration ( ⁇ 220mg/mL) ( Figure 5).
  • %HMW results were consistent across all agitated formulations (Figure 6).
  • the unagitated control vials show a gradual increase in HMW as the % polysorbate-80 drops from 0.05% to 0.00%. All results are within the variability (noise) of the method ( ⁇ 0.2%) and may not be real differences. Stability is comparable across a broad range of % Polysorbate-80.
  • the control Aducanumab formulation has 165mg/mL Aducanumab, 20mM Histidine, 150 mM L-Arginine HC1, lOmM Methionine, 0.05% Polysorbate-80, pH 5.5.
  • the control formulation was spiked with thiol group containing excipients: GSH and GSSG.
  • the formulations were stored at 25°C at 60% relative humidity. As shown in Figure 7, the addition of GSH and GSSG reduces the development of HMW species during storage.
  • a control Aducanumab formulation contains 165 mg/mL Aducanumab, 20 mM Histidine, 150 mM L-Arginine HC1, 10 mM Methionine, 0.05% Polysorbate-80, pH 5.5. This formulation was spiked with GSH + GSSG, GSH alone, or GSSG alone. The formulations were stored at 25°C at 60% relative humidity. As shown in Figure 9, the addition of GSH, GSSG, and GSH+ GSSG all reduced the formation of HMW species.
  • a control Aducanumab formulation has 165mg/mL Aducanumab, 20mM Histidine, 150mM L-Arginine HC1, pH 5.5. GSH or GSH + Methionine were added to the control formulation. These formulations were stored at 25°C at 60% relative humidity. The addition of methionine did not provide any additive benefit to the reduction in HMW species observed with GSH alone ( Figure 10).
  • Aducanumab (165 or 200 mg/mL Aducanumab, 20 mM Histidine, 150 mM L- Arginme HC1, 10 mM Methionine, 0.05% Polysorbate-80, pH 5.5) was stored at 25°C at 60% relative humidity with various concentrations of GSH. As shown in Figure 11, GSH suppresses HMW species formation at concentrations from 0.2 mM to 1.0 mM, at protein concentrations up to 200 mg/ml.
  • Aducanumab (165 or 225 mg/mL Aducanumab, 20mM Histidine, 150mM L- Arginine HC1, lOmM Methionine, 0.05% Polysorbate-80, pH 5.5) was stored at 25°C at 60% relative humidity with various concentrations of GSH.
  • GSH suppresses HMW species formation at concentrations as low as 0.02 mM in formulations containing up to 225 mg/ml Aducanumab.
  • All tested formulations contained 210 mg/mL aducanumab. 20 mM histidine. 150 mM arginine. 10 mM methionine, and 0.05% polysorbate-80. and only differed bv the GSH concentration.
  • the GSH concentrations tested were 0 mM. 0.5 mM. 1 mM. 2 mM. and 4 mM. Samples were stored at 25°C. 60% relative humidity for up to 4.5 months.
  • All tested formulations contained 165 mg/mL aducanumab. 20 mM histidine. 150 mM arginine. and 0.05% polysorbate-80. and only differed bv the concentration of methionine or GSH as shown in Figure 14. Samples were stored at 25°C. 60% relative humidity (top) and 40°C. 75% relative humidity (bottom) for up to 3.5 months.
  • Example 13 A 4-Week Tolerability and Toxico kinetic Study of BIIB037 when
  • the objective of this study was to determine the tolerability of BIIB037 (150 mg/mL strength in 20 mM histidine buffer [16.2 mM L-histidine monohydrate, 3.8 mM L-histidine free base], 150 mM L-arginine hydrochloride (HC1), 10 mM methionine, and 0.05% polysorbate 80 pH 5.5) when given by intravenous (IV) or subcutaneous (SC) injection once a week for 4 weeks to 3 cynomolgus monkeys per group.
  • IV intravenous
  • SC subcutaneous

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2018/047508 2017-08-22 2018-08-22 PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES Ceased WO2019040612A1 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SG11202001281WA SG11202001281WA (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
KR1020257011023A KR20250053967A (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물
LTEPPCT/US2018/047508T LT3672631T (lt) 2017-08-22 2018-08-22 Farmacinės kompozicijos, kurių sudėtyje yra antikūnų prieš beta amiloidą
RS20230487A RS64289B1 (sr) 2017-08-22 2018-08-22 Farmaceutske kompozicije koje sadrže anti-amiloid beta antitela
PL18762749.2T PL3672631T3 (pl) 2017-08-22 2018-08-22 Kompozycje farmaceutyczne zawierające przeciwciała przeciw beta-amyloidowi
EP18762749.2A EP3672631B9 (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
CN201880066191.8A CN111201037B (zh) 2017-08-22 2018-08-22 含有抗β淀粉样蛋白抗体的药物组合物
CA3073066A CA3073066A1 (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
MYPI2020000935A MY204563A (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
EA202090555A EA202090555A1 (ru) 2017-08-22 2018-08-22 Фармацевтические композиции, содержащие антитела к бета-амилоиду
AU2018321335A AU2018321335B2 (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
US16/639,338 US11655289B2 (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
SI201830903T SI3672631T1 (sl) 2017-08-22 2018-08-22 Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
ES18762749T ES2945165T3 (es) 2017-08-22 2018-08-22 Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides
MA49947A MA49947B1 (fr) 2017-08-22 2018-08-22 Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
KR1020207007477A KR102931172B1 (ko) 2017-08-22 2018-08-22 항-베타 아밀로이드 항체를 함유하는 약제학적 조성물
JP2020511254A JP7263320B2 (ja) 2017-08-22 2018-08-22 抗ベータアミロイド抗体を含有する医薬組成物
DK18762749.2T DK3672631T5 (da) 2017-08-22 2018-08-22 Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
BR112020003572-6A BR112020003572A2 (pt) 2017-08-22 2018-08-22 composições farmacêuticas contendo anticorpos anti-beta-amiloide
FIEP18762749.2T FI3672631T3 (fi) 2017-08-22 2018-08-22 Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
MX2020001855A MX2020001855A (es) 2017-08-22 2018-08-22 Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
SM20230129T SMT202300129T1 (it) 2017-08-22 2018-08-22 Composizioni farmaceutiche contenenti anticorpi anti-beta amiloide
IL272773A IL272773B2 (en) 2017-08-22 2018-08-22 Pharmaceutical preparations containing anti-amyloid cell antibodies
MDE20200677T MD3672631T3 (ro) 2017-08-22 2018-08-22 Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
HRP20230387TT HRP20230387T1 (hr) 2017-08-22 2018-08-22 Farmaceutski pripravci koji sadrže anti-beta amiloidna antitijela
EP23163774.5A EP4233901A3 (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
CN202410311745.3A CN118370815A (zh) 2017-08-22 2018-08-22 含有抗β淀粉样蛋白抗体的药物组合物
JOJO/P/2020/0041A JOP20200041B1 (ar) 2017-08-22 2020-02-20 تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
CONC2020/0002992A CO2020002992A2 (es) 2017-08-22 2020-03-13 Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides
JP2022211705A JP2023030173A (ja) 2017-08-22 2022-12-28 抗ベータアミロイド抗体を含有する医薬組成物
US18/300,339 US20240043513A1 (en) 2017-08-22 2023-04-13 Pharmaceutical compositions containing anti-beta amyloid antibodies
JP2025124021A JP2025175284A (ja) 2017-08-22 2025-07-24 抗ベータアミロイド抗体を含有する医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548583P 2017-08-22 2017-08-22
US62/548,583 2017-08-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/639,338 A-371-Of-International US11655289B2 (en) 2017-08-22 2018-08-22 Pharmaceutical compositions containing anti-beta amyloid antibodies
US18/300,339 Continuation US20240043513A1 (en) 2017-08-22 2023-04-13 Pharmaceutical compositions containing anti-beta amyloid antibodies

Publications (1)

Publication Number Publication Date
WO2019040612A1 true WO2019040612A1 (en) 2019-02-28

Family

ID=63449734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/047508 Ceased WO2019040612A1 (en) 2017-08-22 2018-08-22 PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES

Country Status (29)

Country Link
US (2) US11655289B2 (https=)
EP (2) EP4233901A3 (https=)
JP (3) JP7263320B2 (https=)
KR (2) KR20250053967A (https=)
CN (2) CN118370815A (https=)
AU (1) AU2018321335B2 (https=)
BR (1) BR112020003572A2 (https=)
CA (1) CA3073066A1 (https=)
CO (1) CO2020002992A2 (https=)
DK (1) DK3672631T5 (https=)
EA (1) EA202090555A1 (https=)
ES (1) ES2945165T3 (https=)
FI (1) FI3672631T3 (https=)
HR (1) HRP20230387T1 (https=)
HU (1) HUE061510T2 (https=)
IL (1) IL272773B2 (https=)
JO (1) JOP20200041B1 (https=)
LT (1) LT3672631T (https=)
MA (1) MA49947B1 (https=)
MD (1) MD3672631T3 (https=)
MX (2) MX2020001855A (https=)
MY (1) MY204563A (https=)
PL (1) PL3672631T3 (https=)
PT (1) PT3672631T (https=)
RS (1) RS64289B1 (https=)
SG (1) SG11202001281WA (https=)
SI (1) SI3672631T1 (https=)
SM (1) SMT202300129T1 (https=)
WO (1) WO2019040612A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519223B2 (en) 2016-11-03 2019-12-31 Jannsen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
US11236155B2 (en) 2019-03-26 2022-02-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
JP2022524814A (ja) * 2019-03-11 2022-05-10 バイオジェン・エムエイ・インコーポレイテッド 抗ｌｉｎｇｏ－１抗体を含む医薬組成物
US11434285B2 (en) 2020-07-23 2022-09-06 Othair Prothena Limited Anti-Abeta antibodies
EP4373576A1 (en) * 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2025064824A1 (en) * 2023-09-22 2025-03-27 Biogen Ma Inc. Methods for treating alzheimer's disease
EP4121007B1 (en) 2020-03-20 2025-07-02 Eisai R&D Management Co., Ltd. High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12534532B2 (en) * 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
EP4626903A1 (en) * 2022-12-02 2025-10-08 Seattle Project Corp. Compositions and methods of use thereof
AU2024342922A1 (en) 2023-09-15 2026-04-23 Othair Prothena Limited Cell penetrating agents and uses thereof
KR20250136262A (ko) 2024-03-06 2025-09-16 일리미스테라퓨틱스 주식회사 엔지니어링된 tam 수용체 리간드 폴리펩티드 및 이의 용도

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5849992A (en) 1993-12-20 1998-12-15 Genzyme Transgenics Corporation Transgenic production of antibodies in milk
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2008086395A2 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
US8906367B2 (en) 2007-01-05 2014-12-09 University Of Zurich Method of providing disease-specific binding molecules and targets

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JP4878664B2 (ja) 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
AU3117799A (en) 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6187309B1 (en) 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
US6436401B1 (en) 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
WO2001031056A2 (fr) 1999-10-27 2001-05-03 Universite De Liege Methode de detection par pcr
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030028904A1 (en) 2001-04-19 2003-02-06 Gumienny Tina L. Genes involved in engulfment of dying cells and cell migration
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
US7414111B2 (en) 2001-09-19 2008-08-19 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP4662719B2 (ja) 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
CA2492143A1 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DE60331101D1 (de) 2002-11-22 2010-03-11 Chugai Pharmaceutical Co Ltd Antikörper gegen geschädigtes gewebe
US20060240485A1 (en) 2003-04-24 2006-10-26 Universitat Zurich Method of monitoring immunotherapy
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
AU2005217596B2 (en) 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
WO2005105998A1 (ja) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20060062859A1 (en) 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
BRPI0606867A2 (pt) 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2006094724A2 (en) 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
WO2006116192A2 (en) 2005-04-21 2006-11-02 Medarex, Inc. Irta-1 antibodies and their uses
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2008020864A2 (en) 2005-11-14 2008-02-21 The Trustees Of Columbia University In The City Of New York Imaging correlates of neurogenesis with mri
CA2630964A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US8263558B2 (en) 2005-11-30 2012-09-11 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
US8519106B2 (en) 2007-03-13 2013-08-27 University Of Zurich Monoclonal human tumor-specific antibody
US20080292625A1 (en) 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2008309778A (ja) 2007-05-11 2008-12-25 Daiichi Sankyo Co Ltd ポリペプチドの検出又は定量方法、及び装置
CN101778867A (zh) 2007-06-08 2010-07-14 地中海大学 用于治疗胰腺肿瘤的组合物和方法
US8022268B2 (en) 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009033743A1 (en) 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
TW200927761A (en) 2007-09-26 2009-07-01 U3 Pharma Ag Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
US8466265B2 (en) 2007-10-02 2013-06-18 Csl Limited Therapeutic antibody purification method and method of use
US7771957B2 (en) 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
JPWO2009051220A1 (ja) 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
US8343493B2 (en) 2007-10-29 2013-01-01 Innogenetics N.V. Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs
DK2207568T3 (en) 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009094592A2 (en) 2008-01-23 2009-07-30 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
HUE031944T2 (en) 2008-02-08 2017-08-28 Immunas Pharma Inc Antibodies capable of specific binding of amyloid β-oligomers and their use
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CA2730073A1 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
CA2737667A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Targeted binding agents directed to cd105 and uses thereof
PL2365804T3 (pl) 2008-11-13 2015-10-30 Modgene Llc Zmniejszanie obciążenia amyloidem-beta w tkance niemózgowej
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CN102459335B (zh) 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
US20110237537A1 (en) 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
CA2765220A1 (en) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
JP5599454B2 (ja) 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
WO2011064225A1 (en) 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment
EP2510098B1 (en) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
WO2011076854A1 (en) 2009-12-22 2011-06-30 Probiodrug Ag CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN
WO2012005838A1 (en) 2010-07-07 2012-01-12 Thermo Fisher Scientific Gmbh Analyte mass spectrometry quantitation using a universal reporter
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
WO2012174262A2 (en) 2011-06-14 2012-12-20 Cenestra Llc Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
US20130164367A1 (en) 2011-12-08 2013-06-27 The Board Of Regents Of The University Of Texas System Treatment of neurodegenerative disease with creb-binding protein
ES2564281T3 (es) 2012-03-08 2016-03-21 F. Hoffmann-La Roche Ag Formulación de anticuerpos Abeta
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EA201590459A1 (ru) 2012-09-12 2015-11-30 Нейриммьюн Холдинг Аг Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
JP6541581B2 (ja) 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 低濃度抗体製剤
US20140272950A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict ssri response
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
LT2994160T (lt) 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
US20160177390A1 (en) 2013-07-12 2016-06-23 Biogen International Neuroscience Gmbh Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
US10344080B2 (en) 2013-12-20 2019-07-09 Neurimmune Holding Ag Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
RU2724190C2 (ru) 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
EP4406549A3 (en) 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
WO2016040903A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
DK3430397T3 (da) 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5849992A (en) 1993-12-20 1998-12-15 Genzyme Transgenics Corporation Transgenic production of antibodies in milk
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
US8906367B2 (en) 2007-01-05 2014-12-09 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008086395A2 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
WO2011104381A2 (en) * 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
GREGORY; HALLIDAY, NEUROTOX RES., vol. 7, no. 1-2, 2005, pages 29 - 41
HAMPEL ET AL., EXP NEUROL., vol. 223, no. 2, 2010, pages 334 - 46
HOCK, DIALOGUES CLIN NEUROSCI, vol. 5, no. 1, 2003, pages 27 - 33
KAUFMAN; SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621
LEI ET AL., J. BACTERIOL., vol. 169, 1987, pages 4379
MEYER-LUEHMANN, JNEUROSCI, vol. 29, no. 40, 2009, pages 12636 - 40
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
POWERS ET AL., J IMMUNOL METHODS., vol. 251, 2001, pages 123 - 35
SELKOE, COLD SPRING HARB PERSPECT BIOL., vol. 3, no. 7, 2011, pages a004457
SORINA MORAR-MITRICA ET AL: "Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration", MABS, vol. 7, no. 4, 14 June 2015 (2015-06-14), US, pages 792 - 803, XP055516367, ISSN: 1942-0862, DOI: 10.1080/19420862.2015.1046664 *
URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519223B2 (en) 2016-11-03 2019-12-31 Jannsen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
US10851156B2 (en) 2016-11-03 2020-12-01 Janssen Pharmaceutica Nv Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies
US11673943B2 (en) 2016-11-03 2023-06-13 Janssen Pharmaceutica Nv Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
JP2022524814A (ja) * 2019-03-11 2022-05-10 バイオジェン・エムエイ・インコーポレイテッド 抗ｌｉｎｇｏ－１抗体を含む医薬組成物
US11236155B2 (en) 2019-03-26 2022-02-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
EP4121007B1 (en) 2020-03-20 2025-07-02 Eisai R&D Management Co., Ltd. High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
US11434283B2 (en) 2020-07-23 2022-09-06 Othair Prothena Limited Anti-abeta antibodies
US11440953B2 (en) 2020-07-23 2022-09-13 Othair Prothena Limited Anti-abeta antibodies
US11434284B2 (en) 2020-07-23 2022-09-06 Othair Prothena Limited Anti-Abeta antibodies
US11434285B2 (en) 2020-07-23 2022-09-06 Othair Prothena Limited Anti-Abeta antibodies
US12435129B2 (en) 2020-07-23 2025-10-07 Othair Prothena Limited Anti-Aβ antibodies
EP4373576A1 (en) * 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
WO2025064824A1 (en) * 2023-09-22 2025-03-27 Biogen Ma Inc. Methods for treating alzheimer's disease

Also Published As

Publication number Publication date
CN111201037B (zh) 2024-04-02
CA3073066A1 (en) 2019-02-28
MY204563A (en) 2024-09-04
HUE061510T2 (hu) 2023-07-28
JP7263320B2 (ja) 2023-04-24
US20210188954A1 (en) 2021-06-24
MX2024010300A (es) 2024-08-28
IL272773A (en) 2020-04-30
JP2025175284A (ja) 2025-12-01
AU2018321335B2 (en) 2025-08-14
JP2020531520A (ja) 2020-11-05
SI3672631T1 (sl) 2023-06-30
AU2018321335A1 (en) 2020-02-27
SMT202300129T1 (it) 2023-05-12
JP2023030173A (ja) 2023-03-07
EA202090555A1 (ru) 2020-06-08
SG11202001281WA (en) 2020-03-30
PT3672631T (pt) 2023-05-23
EP3672631B1 (en) 2023-03-29
CO2020002992A2 (es) 2020-06-19
KR20250053967A (ko) 2025-04-22
MD3672631T2 (ro) 2023-06-30
FI3672631T3 (fi) 2023-06-29
LT3672631T (lt) 2023-04-25
US11655289B2 (en) 2023-05-23
MX2020001855A (es) 2020-08-13
HRP20230387T1 (hr) 2023-07-07
MD3672631T3 (ro) 2023-09-30
EP4233901A3 (en) 2023-09-06
US20240043513A1 (en) 2024-02-08
IL272773B1 (en) 2024-02-01
EP3672631B9 (en) 2023-06-28
EP3672631A1 (en) 2020-07-01
IL272773B2 (en) 2024-06-01
KR20200044023A (ko) 2020-04-28
MA49947A (fr) 2021-04-21
KR102931172B1 (ko) 2026-02-27
DK3672631T3 (da) 2023-07-03
ES2945165T3 (es) 2023-06-28
BR112020003572A2 (pt) 2020-08-25
CN111201037A (zh) 2020-05-26
PL3672631T3 (pl) 2023-06-26
RS64289B1 (sr) 2023-07-31
MA49947B1 (fr) 2023-03-31
CN118370815A (zh) 2024-07-23
JOP20200041B1 (ar) 2024-04-18
DK3672631T5 (da) 2024-08-26
JOP20200041A1 (ar) 2020-02-20
EP4233901A2 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
US20240043513A1 (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
EP1853310B1 (en) Anti a beta antibody formulation
JP2020512368A (ja) シヌクレイノパチーを治療するための組成物及び方法
KR20240042443A (ko) 신경계 질환을 치료하는 방법
HK40100459A (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
HK40022704A (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
HK40022704B (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
EA051676B1 (ru) Фармацевтические композиции, содержащие антитела к бета-амилоиду
TW202342098A (zh) 含有ｐｄ－１抗體的穩定高濃度氯化鈉配製物及其使用方法
HK1108132B (en) Anti a beta antibody formulation
HK1118723B (en) Anti a beta antibody formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18762749

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3073066

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122021016344

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020511254

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018321335

Country of ref document: AU

Date of ref document: 20180822

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020003572

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20207007477

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2020/0002992

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2020000174

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2018762749

Country of ref document: EP

Effective date: 20200323

WWP Wipo information: published in national office

Ref document number: NC2020/0002992

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112020003572

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200220

WWG Wipo information: grant in national office

Ref document number: NC2020/0002992

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 520411321

Country of ref document: SA

WWD Wipo information: divisional of initial pct application

Ref document number: 1020257011023

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020257011023

Country of ref document: KR

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020257011023

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020257011023

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 520411321

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 520411321

Country of ref document: SA